Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2025 09:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell...
November 07, 2025 06:47 ET | Source: Research and Markets

$13.5+ Bn Cancer Gene Therapy Markets - Global Industry Share, Trends, Opportunities, and Forecasts, 2020-2030F

Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
November 05, 2025 04:08 ET | Source: Research and Markets

Precision Oncology Research Report 2025: Market to Hit $158.9 Billion by 2029 as Genomics Diagnostics, Liquid Biopsies, Single-Cell Sequencing and Patient-Specific Cancer Vaccines Accelerate Adoption

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Precision Oncology Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The precision oncology market size has grown rapidly...
November 04, 2025 11:36 ET | Source: Research and Markets

Gastric Cancer Global and Regional Market Analysis 2025-2035: Focus on Treatment Type and End User with Profiles of Daiichi Sankyo, AstraZeneca, Roche, Merck & Co., Eli Lilly & Company and More

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market - A Global and Regional Analysis: Focus on Treatment Type, End User, and Region - Analysis and Forecast, 2025-2035" has been...
November 04, 2025 10:00 ET | Source: PersonaDx

PersonaDx Co-Founder Dr. Sean Pitroda Awarded $1 Million Falk Medical Research Trust Grant

Chicago, IL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- PersonaDx, a precision diagnostic oncology company transforming how metastatic cancers are classified and treated, announced today that its co-founder...
October 22, 2025 03:00 ET | Source: Onco3R Therapeutics BV

Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2...
October 13, 2025 07:59 ET | Source: Research and Markets

Conjugated Drugs (XDCs) in Oncology Market Intelligence Tool Launched – Covering 2,500+ Pipeline Drugs and 1,300+ Funding Rounds

Dublin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of Conjugated Drugs (XDCs) in Oncology with Confidence" directory has been added to ...
October 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...
October 01, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States

Basel, Switzerland / Munich, Germany, October 01, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it...
September 30, 2025 08:40 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first...